Citius Pharma closes $6.0M registered direct offering under Nasdaq rules, furthers critical care product development.
Citius Pharmaceuticals Inc., a biopharmaceutical company listed on Nasdaq under the ticker symbol CTXR, based in Cranford, New Jersey, disclosed on October 21, 2025, the successful completion of a significant corporate milestone. This milestone marks the closure of a financial transaction or possibly a strategic partnership that is crucial for the Company's advancement. Citius Pharma focuses on pioneering critical care products and aims to bring them to market. The Company's dedication to developing innovative medical solutions is evident in this recent development, demonstrating progress in their mission.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments